ECM
CTMX icon

ExodusPoint Capital Management’s CytomX Therapeutics CTMX Stock Holding History

ExodusPoint Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,049
Closed -$24K – 1603
2024
Q1 		$24K Buy
+11,049
New +$20.4K ﹤0.01% 1441
2022
Q3 		– Sell
-162,990
Closed -$298K – 1944
2022
Q2 		$298K Buy
162,990
+135,810
+500% +$260K ﹤0.01% 1541
2022
Q1 		$73K Sell
27,180
-80,185
-75% -$308K ﹤0.01% 2032
2021
Q4 		$465K Buy
107,365
+69,873
+186% +$409K ﹤0.01% 1461
2021
Q3 		$191K Buy
37,492
+11,268
+43% +$60.3K ﹤0.01% 1797
2021
Q2 		$166K Buy
+26,224
New +$204K ﹤0.01% 2036
2021
Q1 		– Sell
-41,728
Closed -$273K – 2183
2020
Q4 		$273K Buy
41,728
+12,365
+42% +$88.3K ﹤0.01% 1586
2020
Q3 		$195K Buy
29,363
+12,893
+78% +$95.6K ﹤0.01% 1487
2020
Q2 		$137K Buy
+16,470
New +$153K ﹤0.01% 1591
2020
Q1 		– Sell
-33,879
Closed -$282K – 1165
2019
Q4 		$282K Buy
33,879
+4,245
+14% +$28.6K 0.01% 1171
2019
Q3 		$219K Buy
29,634
+8,904
+43% +$87.8K 0.01% 1077
2019
Q2 		$233K Buy
+20,730
New +$217K 0.01% 830

Other funds holding CTMX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

ExodusPoint Capital Management's CTMX Position: Q2 2024 in Review

ExodusPoint Capital Management sold out of CytomX Therapeutics (CTMX) in Q2 2024, closing a stake of 11,049 shares — an estimated $24K sold.

ExodusPoint Capital Management first reported a position in CTMX in Q2 2019 and held it in 12 quarters. The position peaked at $465K in Q4 2021. 74 funds tracked by Wall St. Rank hold CTMX as of Q2 2024.

  • ExodusPoint Capital Management reported no remaining CytomX Therapeutics position as of Q2 2024 after selling out during the quarter.
  • ExodusPoint Capital Management sold 11,049 CytomX Therapeutics shares in Q2 2024, an estimated $24K.
  • ExodusPoint Capital Management first reported a position in CytomX Therapeutics in Q2 2019 and held it in 12 quarters.
  • ExodusPoint Capital Management's CytomX Therapeutics position peaked at $465K in Q4 2021.
  • 74 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2024.

Based on ExodusPoint Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.